Neurologic Manifestations of Long COVID Differ Based on Acute COVID-19 Severity
Ann Neurol 94:146-159, Giraldo,G.S.P.,et al, 2023
The COVID-19 Pandemic and the Ethical Duties of the Neurologist
Neurol 95:167-172, Rubin, M.A.,et al, 2020
Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging
NEJM 378:708-718, Albers, G.W.,et al, 2018
Subarachnoid Hemorrhage
NEJM 377:257-266, Lawton, M.T. & Vates, G.E., 2017
Practice Guideline Update Summary: Botulinum Neurotoxin for the Treatment of Blepharospasm, Cervical Dystonia, Adult Spasticity, and Headache
Neurol 86:1818-1826, Simpson, D.M.,et al, 2016
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Assessment and Management of Behavioral and Psychological Symptoms of Dementia
BMJ 350:h369, Kales, H.C.,et al, 2015
Palliative and End-Of-Life Care in Stroke
Stroke 45:1887-1916, Holloway, R.G.,et al, 2014
Early Surgical Therapy for Drug-Resistant Temporal Lobe Epilepsy
JAMA 307:922-930, Engel, J.,et al, 2012
Long-Term Survival with Favorable Cognitive Outcome After Chemotherapy in Primary Central Nervous System Lymphoma
Ann Neurol 67:182-189, Juergens,A.,et al, 2010
Responding to Requests from Adult Patients for Neuroenhancements
Neurol 73:1406-1412, Larriviere,D.,et al, 2009
Practice Parameter Update: The Care of the Patient with Amyotrophic Lateral Sclerosis: Drug, Nutritional, and Respiratory Therapies (An Evidence-Based Review)
Neurol 73:1218-1226, Miller,R.G.,et al, 2009
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
Health-Related Quality of Life in Multiple Sclerosis: Effects of Natalizumab
Ann Neurol 62:335-346, Rudick,R.A.,et al, 2007
Central Nervous System Injury Associated with Cardiac Surgery
Lancet 368:694-703, Newman,M.F.,et al, 2006
High-Dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis
Arch Neurol 63:1388-1393, Gladstone,D.E.,et al, 2006
Cognitive Status and Quality of Life After Treatment for Primary CNS Lymphoma
Neurol 62:544-547,532, Harder,H.,et al, 2004
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Pharmaceutical Interventions for Emotionalism After Stroke
Stroke 35:2610-2611, Horrocks,J.A.,et al, 2004
Disability and Quality of Life in Charcot-Marie-Tooth Disease Type 1
JNNP 70:548-550, Pfeiffer,G.,et al, 2001
What Contributes to Quality of Life in Patients with Parkinson's Disease?
JNNP 69:308-312,289, Schrag,A. et al, 2000
Health Outcomes 1 Year After Subarachonid Hemorrhage
Neurol 55:658-662, Hackett,M.L. et al, 2000
Efficacy and Safety of Rivastigmine in Patients with Alzheimer's Disease:International Randomised Controlled
BMJ 318:633-640, 615, Rosler,M.,et al, 1999
Changes in Resource Use and Outcomes for Patients with Migraine Treated with Sumatriptan, A Managed Care Perspective
Arch Int Med 159:857-863, Lofland,J.H.,et al, 1999
Practice Parameter:The Care of the Patient with Amyotrophic Lateral Sclerosis (An Evidence-Based Review), Report of the Quality Standards Subcommittee of the AAN
Neurol 52:1311-1323, Miller,R.G.,et al, 1999
Tube Feeding in Patients with Advanced Dementia,A Review of the Evidence
JAMA 282:1365-1370, Finucane,T.E.,et al, 1999
Recovery Following Lateral Medullary Infarction
Neurol 50:1418-1422, Nelles,G.,et al, 1998
Quality of Life in Patients and Partners After Aneurysmal Subarachnoid Hemorrhage
Stroke 29:798-804, Hopp,J.W.,et al, 1998
A 29-Year-Old Man with Multiple Sclerosis
JAMA 280:1432-1439, Rudick,R.A., 1998
Doctors & Pts Don't Agree:Cross Sectional Study of Pts' & Doctors'Perceptions & Assessments of Disability in MS
BMJ 314:1580-1583, Rothwell,P.M.,et al, 1997
Treatment of Advanced Parkinson's Disease by Posterior GPi Pallidotomy:1-Year Results of a Pilot Study
Ann Neurol 40:355-366, 3411996., Baron,M.S.,et al, 1996
Neurodevelopmental Outcome of Infants with Hypoplastic Left Heart Syndrome
J Pediatr 126:496-498, Rogers,B.T.,et al, 1995
Prognosis of Young Adults with Ischemic Stroke:Follow-up Assessing Recurrent Vascular Events & Funct Outcome
Stroke 25:1360-1365, Kappelle,L.J.,et al, 1994
Neurologic Manifestations of HIV Infection
Ann Int Med 121:769-785, Simpson,D.M.&Tagliati,M., 1994
A Comparison of Five Stroke Scales with Measures of Disability, Handicap, and Quality of Life
Stroke 24:1178-1181, DeHaan,R.,et al, 1993
Evaluation of the Effects of Vigabatrin on Cognitive Abilities and Quality of Life in Epilepsy
Neurol 43:2501-2507, Dodrill,C.B.,et al, 1993
The Psychological Consequences of Predictive Testing for Huntington's Disease
NEJM 327:1401-1405, 14491992., Wiggins,S.,et al, 1992
Quality of Life in Multiple Sclerosis, Comparison with Inflam Bowel Dis & Rheumatic Arthritis
Arch Neurol 49:1237-1242, Rudick,R.A.,et al, 1992
Recombinant Human Erythropoietin and Renal Anemia:Molecular Biology, Clinical Efficacy, and Nervous System Effects
Ann Int Med 114:402-416, Nissenson,A.R.,et al, 1991
Cognitive Dysfunction in MS, II. Impact on Employment and Social Functioning
Neurol 41:692-696, Rao,S.M.,et al, 1991
Social and Family Integration of Hemiplegic Elderly Patients 1 Year After Stroke
Stroke 21:1019-1022, Santus,G.,et al, 1990
Neurologic Sequelae of Open-Heart Surgery in Children
Am J Dis Child 144:369-373, Ferry,P.C., 1990
Quality of Life 4 Years After Stroke
Stroke 19:1101-1107, Niemi,M.L.,et al, 1988